Abualbishr Alshreef

Associate Director, HEOR Strategy at AbbVie. All views my own.

[Abualbishr Alshreef @AbuAlshreef]

@Blue_Footy Hhh guy bell c).?:.3&.’jddndjxjxkdj

[Abualbishr Alshreef @AbuAlshreef]

Attending #ISPORAnnual in DC or virtually?
Join me tomorrow for our virtual poster session on Monday, May 16, 3:00 – 6:30 PM EDT!

#HEOR #HTA #MedicationAdherence

[Abualbishr Alshreef @AbuAlshreef]

@HughesDyfrig @NRLatimer @ScHARRHEDS Thank you Prof Dyfrig Hughes @HughesDyfrig for your advice and comments.

[Abualbishr Alshreef @AbuAlshreef]

Passed my PhD viva today!

Super thank you to my supervisors; Prof Simon Dixon, Prof Paul Tappenden, Dr Nick Latimer @NRLatimer and Dr Will McKane.

#HealthEconomics #HTA @ScHARRHEDS #PhDone

[Abualbishr Alshreef @AbuAlshreef]

A huge thank you to the external examiners; Prof Keith Abram @KRAbrams and Dr Alec Miners, plus the viva internal coordinator; Prof Allan Wailoo @AllanWailoo

[Eline Krijkamp @eKrijkamp]

In his presentation, @AbuAlshreef, explains why G-methods are the best-performing methods for adjusting estimates of treatment effectiveness for patient non-adherence in the context of time-to-event outcomes and health technology assessment. #simulationstudy #SMDM21

[Abualbishr Alshreef @AbuAlshreef]

So excited to be presenting at the SMDM 43rd Annual North American Meeting tomorrow (11:15 AM EDT)!

#MedicationAdherence #SMDM21 @socmdm @ScHARRHEDS

[SCHARR HEDS @SCHARRHEDS]

New research publication in The Lancet Psychiatry co-authors HEDS Health Economist Anju Keetharuth and HEDS Research Associate Nyantara Wickramasekera
@ScHARRHEDS
@ScHARRSheffield
https://t.co/5XE2AZ2u7o

[SCHARR HEDS @SCHARRHEDS]

.@ScHARRHEDS contribute to a new @NIHRresearch Health Technology Assessment: Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: LEAVO non-inferiority three-arm RCT https://t.co/B3xncGXA3i #MacularOedema

[Abualbishr Alshreef @AbuAlshreef]

Clinical and Cost Effectiveness of Intravitreal Ranibizumab (#Lucentis) vs Aflibercept (#Eylea) vs Bevacizumab (#Avastin) for Macular Oedema due to CRVO.

Check out our full #HTA report from the LEAVO study: https://t.co/9kMEjSXNYq

#RCT #healtheconomics #HEOR @ScHARRHEDS

[Abualbishr Alshreef @AbuAlshreef]

“If the estimated 5700 people diagnosed with MO due to CRVO each year in England & Wales (@RCOphth) were treated with bevacizumab instead of aflibercept the #NHS would save £31,692,000 within 1 year £25,906,500 if treated with bevacizumab instead of ranibizumab
#Ophthalmology
3/3

[Abualbishr Alshreef @AbuAlshreef]

Bevacizumab (#Avastin) is always the most cost-effective intervention compared to ranibizumab and aflibercept for the treatment of macular oedema (MO) due to CRVO: LEAVO Study

Checkout our new paper in @PECjournal: https://t.co/sUIjgTSDV8

#healtheconomics #HTA @SchARRHEDS
1/3

[Abualbishr Alshreef @AbuAlshreef]

“Although bevacizumab was not non-inferior to ranibizumab & aflibercept in LEAVO, the three interventions generate similar quality-adjusted life-years
Wider adoption of bevacizumab for the treatment of MO due to CRVO could result in substantial savings to healthcare systems
2/3

[Munya Dimairo @mdimairo]

For those interested in understanding the cost-effectiveness of self-managed computerised word finding therapy as an add-on to usual care for people with aphasia post-stroke. Kudos to @BigCACTUS_study team @NRLatimer @RPalmerSLT @StevenJulious et al.

https://t.co/nwsLDaSq1r

[The Lancet @TheLancet]

Just added to The Lancet's #COVID19 Resource Centre—Safety and immunogenicity of two COVID-19 vaccine trials: ChAdOx1 https://t.co/qzlBcVGaGj and adenovirus type-5 vectored https://t.co/X0TmwFTxBd plus linked Comment https://t.co/wAfiTSqAEU

[Martin Landray @MartinLandray]

#RECOVERYtrial #Dexamethasone
Pre-print now available.
Huge credit to all those #NHS who have made this possible - most of all to the patients, their families and their loved ones. Thank you all.

https://t.co/M1FUQehsgc

[Munya Dimairo @mdimairo]

Our paper is now out @bmj_latest & Trials @BioMedCentral

The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design https://t.co/iAj4PYovke

https://t.co/UsWMemTM5p

[Oxford Population Health (OxPop) @Oxford_NDPH]

#RECOVERYTrial: Low-cost dexamethasone reduces deaths by up to a third in hospitalised #COVID19 patients with severe respiratory complications.

Read statement from the Chief Investigators ➡��� https://t.co/yylaEPEWs3

[The Lancet @TheLancet]

Vaccine makers are racing to develop #COVID19 vaccines, and have advanced 10 candidates into clinical trials. But challenges remain.

World Report spoke to @drpennyheaton @GatesMRI, CEO of @vaccitech & Adrian Hill, vaccinologist @UniofOxford https://t.co/Q6Ai83SI81

[SCHARR @SCHARRSheffield]

We are proud to launch our first in a series of health research webinars from @ScHARRSheffield starting on June 25th with @Ju_B81 - Change and continuity in the global health system - register your place here https://t.co/6Ktq2MUew6